Rates of Inhibitor development in previously untreated patients with severe hemophilia A treated with plasma-derived or recombinant factor VIII: no proof of difference or proof of no difference?

Semin Thromb Hemost. 2014 Mar;40(2):269-70. doi: 10.1055/s-0034-1367471. Epub 2014 Feb 5.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Factor VIII / adverse effects*
  • Hemophilia A / drug therapy*
  • Humans

Substances

  • Factor VIII